Claims for Patent: 9,125,910

Summary for Patent: 9,125,910

Title:	1-[2-(2,4 dimethylphenylsulfanyl)-phenyl]piperazine as a compound with combined serotonin reuptake, 5-HT.sub.3 and 5-HT.sub.1A activity for the treatment of cognitive impairment
Abstract:	This disclosure relates to a method of treating a disease selected from the group consisting of Alzheimer's disease, cognitive impairment, and attention deficit hyperactivity disorder (ADHD). The method includes administering a therapeutically effective amount of Compound I or a pharmaceutically acceptable salt thereof to patient in need thereof, in which Compound I is 1-[2-(2,4-dimethylphenylsulfanyl)-phenyl]piperazine.
Inventor(s):	Bang-Andersen; Benny (Copenhagen S, DK), Mork; Arne (Malov, DK), Stensbol; Tine Bryan (Vaerlose, DK), Faldt; Andre (Ishoj, DE)
Assignee:	H. Lundbeck A/S (Copenhagen-Valby, DK)
Application Number:	14/481,000
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for patent 9,125,910
Patent Claims:	1. A method of treating cognitive impairment involving decline in speed of processing, executive function, attention, or verbal learning and memory in a patient diagnosed with depression, the method comprising administering a therapeutically effective amount of Compound I or a pharmaceutically acceptable salt thereof to the patient, wherein Compound I is 1-[2-(2,4-dimethylphenylsulfanyl)-phenyl]piperazine and the method alleviates a symptom or complication of the cognitive impairment or delays the progression of the cognitive impairment. 2. The method of claim 1, wherein Compound I or a pharmaceutically acceptable salt thereof is a hydrobromide salt of 1-[2-(2,4-dimethylphenylsulfanyl)-phenyl]piperazine. 3. The method of claim 1, wherein the depression is major depressive disorder. 4. The method of claim 1, wherein the method comprises administering a hydrobromide, hydrochloride, mesylate, fumarate, maleate, meso-tartrate, L-(+)-tartrate, D-(-)-tartrate, sulphate, phosphate or nitrate salt of Compound I to the patient. 5. The method of claim 3, wherein the method comprises administering a hydrobromide, hydrochloride, mesylate, fumarate, maleate, meso-tartrate, L-(+)-tartrate, D-(-)-tartrate, sulphate, phosphate or nitrate salt of Compound I to the patient. 6. The method of claim 3, wherein the method comprises administering a hydrobromide salt of Compound I to the patient. 7. The method of claim 1, wherein the depression is generalized depression. 8. The method of claim 1, wherein the depression is postnatal depression. 9. The method of claim 1, wherein the depression is a depression associated with bipolar disorder. 10. The method of claim 1, wherein the depression is a treatment resistant depression.